Antibody structure, instability, and formulation.

Journal of pharmaceutical sciences (2006-09-26)
Wei Wang, Satish Singh, David L Zeng, Kevin King, Sandeep Nema
ABSTRACT

The number of therapeutic monoclonal antibody in development has increased tremendously over the last several years and this trend continues. At present there are more than 23 approved antibodies on the US market and an estimated 200 or more are in development. Although antibodies share certain structural similarities, development of commercially viable antibody pharmaceuticals has not been straightforward because of their unique and somewhat unpredictable solution behavior. This article reviews the structure and function of antibodies and the mechanisms of physical and chemical instabilities. Various aspects of formulation development have been examined to identify the critical attributes for the stabilization of antibodies.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Mouse IgG (whole molecule) antibody produced in goat, whole antiserum
Sigma-Aldrich
Anti-Human IgG (Fab specific) antibody produced in goat, whole antiserum
Sigma-Aldrich
Anti-Human IgG (whole molecule) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.